Current status of stem cell therapy for type 1 diabetes: a critique and a prospective consideration

Stem Cell Research & Therapy, Journal Year: 2024, Volume and Issue: 15(1)

Published: Jan. 29, 2024

Abstract Over the past decade, there had been progress in development of cell therapy for insulin-dependent diabetes. Nevertheless, important hurdles that need to be overcome still remain. Protocols differentiation pluripotent stem cells into pancreatic progenitors or fully differentiated β-cells have developed. The resulting insulin-producing can control chemically induced diabetes rodents and were subject several clinical trials. However, these are immunogenic possibly teratogenic their transplantation, an immunoisolation device and/or immunosuppression is needed. A growing number studies utilized genetic manipulations produce immune evasive cells. Evidence must provided addition expected benefit, gene should not lead any unforeseen complications. Mesenchymal stem/stromal (MSCs) provide a viable alternative. MSCs widely available from many tissues. They form by directed differentiation. Experimentally, evidence has shown transplantation allogenic derived associated with muted allogeneic response does interfere functionality. This explained immunomodulatory functions MSC subpopulation did differentiate Recently, exosomes naive used experimental domain treat varying degrees success. Several mechanisms beneficial proposed including reduction insulin resistance, promotion autophagy, increase T regulatory population. euglycemia was achieved experiments. We suggest (educated) better therapeutic effect than those undifferentiated

Language: Английский

---

The potency of mesenchymal stem/stromal cells: does donor sex matter?

Stem Cell Research & Therapy, Journal Year: 2024, Volume and Issue: 15(1)

Published: April 22, 2024

Abstract Mesenchymal stem/stromal cells (MSCs) are a promising therapeutic tool in cell therapy and tissue engineering because of their multi-lineage differentiation capacity, immunomodulatory effects, protective potential. To achieve optimal results as tool, factors affecting MSC potency, including but not limited to source, donor age, batch, have been investigated. Although the sex has attributed potential factor that can influence potency efficacy, impact on characteristics carefully In this review, we summarize published studies demonstrating donor-sex-related heterogeneity emphasize importance disclosing key therapy.

Language: Английский

---

Steps toward the clinical application of endometrial and menstrual fluid mesenchymal stem cells for the treatment of gynecological disorders

Expert Opinion on Biological Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 10, 2025

The human endometrium is a highly regenerative tissue that contains mesenchymal stem/stromal cells (MSCs). These MSCs are sourced via office-based biopsies and menstrual fluid providing less invasive readily available option for cell-based therapies. This review provides an update on endometrial-derived as treatment gynecological diseases. narrative covers the characterization therapeutic mechanisms of biopsy-derived (eMSCs) fluid-derived stromal (MenSCs), highlighting similarities differences. It also studies their application in preclinical animal models, clinical trials potential therapies eMSCs MenSCs from homologous source have to promote activity Both demonstrate benefits through paracrine regeneration, immunomodulation, angiogenesis mitigating fibrosis. Further research essential establish standardized isolation protocols, particularly heterogeneous MenSCs, fully understand action. Implementing SUSD2 magnetic bead sorting purifying endometrial tissues crucial use future Optimization production, storage delivery methods will maximize effectiveness.

Language: Английский

---

Advantages of pooling of human bone marrow-derived mesenchymal stromal cells from different donors versus single-donor MSCs

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: June 2, 2024

Abstract Mesenchymal stromal cells (MSC) from adult bone marrow are the most commonly used in clinical trials. MSCs single donors preferred starting material but suffer a major setback of being heterogeneous that results unpredictable and inconsistent outcomes. To overcome this, we developed method pooling different created cell banks to cater needs. Initially, master (MCBs) were at passage 1 (P1) isolated nine donors. At this stage, MCBs three mixed equal proportion expanded till P3 create working banks. Further, pooled individual donor P5 cryopreserved extensively characterised. There was large heterogeneity among terms growth kinetics (90% Coefficient variation (CV) for yield 44% CV population doubling time P5), immunosuppressive ability (30% 1:1 300% 1:10 ratio), angiogenic factor secretion potential (20% VEGF and71% SDF-1). Comparatively, have more stable profiles (60% 7% P5) exhibit better (15% 32% ratio ) consistent factors (16% 51% Further does not compromise trilineage differentiation capacity or phenotypic marker expression MSCs. The senescence vitro tumourigenicity characteristics also similar those We conclude reduces produces with higher profile.

Language: Английский

---

International Society for Cell and Gene Therapy Clinical Translation Committee recommendations on mesenchymal stromal cells in graft-versus-host disease: easy manufacturing is faced with standardizing and commercialization challenges

Cytotherapy, Journal Year: 2024, Volume and Issue: 26(10), P. 1132 - 1140

Published: May 9, 2024

Mesenchymal Stromal Cells (MSCs) have been used in multiple clinical trials for steroid-refractory moderate-severe (grade II-IV) acute Graft-versus-Host Disease (aGvHD) across the world over last 2 decades. Despite very promising results a variety of trials, it failed to get widespread approval by regulatory agencies such as U.S. Food and Drug Administration European Medicines Agency. What lessons can we learn from this future studies on MSCs other cell therapy products? Broad heterogeneity among published using aGVHD was likely core problem. We propose standardized approach regards donor-related factors, MSCs-related characteristics, well trial design, limit fulfill requirements agencies. This may be expanded beyond Cell Gene products diseases.

Language: Английский

---

Mesenchymal stromal cells derived from various tissues: Biological, clinical and cryopreservation aspects: Update from 2015 review

Cryobiology, Journal Year: 2024, Volume and Issue: 115, P. 104856 - 104856

Published: Feb. 8, 2024

Mesenchymal stromal cells (MSCs) have become one of the most investigated and applied for cellular therapy regenerative medicine. In this update our review published in 2015, we show that studies continue to abound regarding characterization MSCs distinguish them from other similar cell types, discovery new tissue sources MSCs, confirmation their properties functions render suitable as a therapeutic. Because cryopreservation is widely recognized only technology would enable on-demand availability here although traditional method cryopreserving by slow cooling presence 10% dimethyl sulfoxide (Me2SO) continues be used many, several novel MSC approaches emerged. As previous review, conclude these recent reports viable functional diverse tissues can recovered after using variety cryoprotectants, freezing protocols, storage temperatures, periods storage. We also logistical reasons there are now more devoted which derived. A topic included covers application COVID-19 arising immunomodulatory antiviral properties. Due inherent heterogeneity populations different still no standardized procedure isolation, identification, characterization, cryopreservation, route administration, not likely "one-size-fits-all" approach applications cell-based

Language: Английский

---

Wharton’s jelly mesenchymal stem cells: Future regenerative medicine for clinical applications in mitigation of radiation injury

World Journal of Stem Cells, Journal Year: 2024, Volume and Issue: 16(7), P. 742 - 759

Published: July 25, 2024

Wharton's jelly mesenchymal stem cells (WJ-MSCs) are gaining significant attention in regenerative medicine for their potential to treat degenerative diseases and mitigate radiation injuries. WJ-MSCs more naïve have a better safety profile, making them suitable both autologous allogeneic transplantations. This review highlights the of clinical applications mitigating various types In this review, we will also describe why become one most probable future along with balanced view on strengths weaknesses. Finally, updated literature related preclinical usage application regeneration tissues organs be compiled.

Language: Английский

---

Innovative Approaches to Boost Mesenchymal Stem Cells Efficacy in Myocardial Infarction Therapy

Materials Today Bio, Journal Year: 2025, Volume and Issue: 31, P. 101476 - 101476

Published: Jan. 9, 2025

Stem cell-based therapy has emerged as a promising approach for heart repair, potentially regenerating damaged tissue and improving outcomes patients with disease. However, the efficacy of stem therapies remains limited by several challenges, including poor cell survival, low retention rates, integration, functional outcomes. This article reviews current enhancement strategies to optimize mesenchymal cardiac repair. Key approaches include optimizing delivery methods, enhancing engraftment, promoting functions through genetic molecular modifications, paracrine effects cells, leveraging biomaterials engineering techniques. By focusing on these techniques, paper highlights innovative that can transform into more viable effective treatment option The ongoing research technological advancements continue push boundaries, hoping make mainstream

Language: Английский

---

Emerging Role of Mesenchymal Stromal Cell and Exosome Therapies in Treating Cognitive Impairment

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(3), P. 284 - 284

Published: Feb. 20, 2025

Cognitive aging, characterized by the gradual decline in cognitive functions such as memory, attention, and problem-solving, significantly impacts daily life. This is often accelerated neurodegenerative diseases, particularly Alzheimer’s Disease (AD) Parkinson’s (PD). AD marked accumulation of amyloid-beta plaques tau tangles, whereas PD involves degeneration dopaminergic neurons. Both conditions lead to severe impairment, greatly diminishing quality life for affected individuals. Recent advancements regenerative medicine have highlighted mesenchymal stromal cells (MSCs) their derived exosomes promising therapeutic options. MSCs possess regenerative, neuroprotective, immunomodulatory properties, which can promote neurogenesis, reduce inflammation, support neuronal health. Exosomes, nanosized vesicles from MSCs, provide an efficient means delivering bioactive molecules across blood–brain barrier, targeting underlying pathologies PD. While these therapies hold great promise, challenges variability MSC sources, optimal dosing, effective delivery methods need be addressed clinical application. The development robust protocols, along with rigorous trials, crucial validating safety efficacy exosome therapies. Future research should focus on overcoming barriers, optimizing treatment strategies, exploring integration lifestyle interventions. By addressing challenges, MSC- exosome-based could offer transformative solutions improving outcomes enhancing individuals aging diseases.

Language: Английский

---

Stem cell approaches for tendon repair: delusion or insight

The Journal of Physiology, Journal Year: 2025, Volume and Issue: unknown

Published: April 11, 2025

Abstract Tendon injuries are a common and significant health burden around the world. Current treatment strategies unable to fully restore tendon structure function. To address these critical clinical needs, stem cell therapy has recently emerged as promising approach for better repair. In this review, we discuss efficacy of in repair by summarizing its advantages disadvantages both preclinical settings. We highlight recent advances improving cell‐based treatment, with focus on research efforts identification appropriate sources, modification effective transplantation, development carriers, standardization protocols. Finally, provide insights into future directions therapy, emphasis necessity employing patient screening criteria before establishing comprehensive outcome measurements ensure rigor trials. image

Language: Английский

---